PURPOSE: To treat a tumor disease under inhibiting undersirable side effects by administering an antibody-enzyme conjugate compound to an onset patient, subsequently administering a substrate-cytotoxic agent wherein the substrate is a substrate for the enzyme to activate the cytotoxic agent at a tumor onset portion.
CONSTITUTION: An antibody-enzyme conjugate compound composed of an antibody (e.g. ZCE 025) which binds to an antigen (e.g. carcinoembryonic antigen) singly or abnormally abundantly expressed by a malignant tumor cell and an enzyme such as β-lactamase, β-galactosidase, etc., is administered to an onset patient and, subsequently, a substrate-cytotoxic agent composed of a substrate for the enzyme (e.g. penicillin, cephalosporin for β-lactamase) and a cytotoxic agent such as methotrexate, 5-fluorouracil, etc., is administered and the substrate is cleaved and separated from the cytotoxic agent by the enzyme of the conjugate present concentratedly at the tumor onset portion to allow the cytotoxic agent selectively to act on the tumor portion.
RUISU NITSUKORAUSU YUNGUHAIMU
DEIMON ROORENSU MEIYAA
TEIMOSHII ARAN SHIEFUAADO
HYBRITECH INC